Having trouble accessing articles? Reset your cache.

Despite outreach to over 18 companies, Lilly was only biopharma to offer Dermira takeout

Dermira’s multiyear quest to find a partner for lebrikizumab found it knocking on the doors of over 18 biopharmas, but only Eli Lilly was interested in submitting a bid to acquire the autoimmune and dermatology company.

SEC documents

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE